Oncology

Recent advances and updates in oncology and cancer drug development.

Xalkori gives new option to patients with the rare and difficult to treat ROS-1 gene mutation in NSCLC.

Expanded use of crizotinib treats patients with ROS1-positive metastatic non–small cell lung cancer.

Harnessing T cells may lead to significant new cancer treatments.

Obesity carries increased risk for diabetes, cardiovascular disease, and lymphomas.

Cancer drug called nutlins activate the P53 gene to trigger blood cancer cell death instead of temporarily suppressing the disease.

Foods with a high glycemic index raise blood sugar levels and stimulate the production of insulin

Signaling pathway may be vital in treating colorectal cancer patients.

Keytruda found to improve overall survival compared with chemotherapy in patients with non-small cell lung cancer.

New colorectal cancer screening guidelines call for biweekly screenings for adults aged 50 to 74 years for colorectal cancer with FOBT or flexible sigmoidoscopy every 10 years.

New method examines the genetic background of tumors for more effective prostate cancer therapy.

Treatment shows promise in fighting lymphoma in early studies.

New analysis provides faster tests and lower costs for women with estrogen positive-receptor (ER-positive) breast cancer.

Recent advances and updates in oncology and cancer drug development.

Ibrutinib (Imbruvica) is the first FDA-approved chemotherapy-free treatment for patients with chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica) is the first chemotherapy-free treatment for first line CLL patients approved by the FDA.

Abraxane treats patients with advanced, squamous non-small cell lung cancer (NSCLC).

With recent therapeutic advances, the treatment landscape for metastatic castration-resistant prostate cancer is changing rapidly.

Durvalumab and tremelimumab was active in patients with or without tumor expression of PD-L1 in NSCLC.

Nanoparticles acting as cancer drug delivery vehicles show promise in eliminating tumors.

Medication spending waste can be reduced with smaller vials of cancer drugs, study finds.

High cost infused cancer drugs are packaged containing quantities larger than needed to treat patients.

Adherence patterns and other risk factors predict increased utilization of acute care by outpatients with cancer pain.

Controversy swirls around the naming protocol for biosimilars among drug manufacturers and the FDA.

Men diagnosed with cancer under age 25 far less likely to have children and more likely to take infertility drugs.

Several chemotherapy agents have been investigated for neoadjuvant use in HER2-positive breast cancer.

Less than half of adolescents and young adults who survive Hodgkin lymphoma receive recommended services within the first year after treatment.

Combination of sialidase and cucurbitacin I shows substantial antitumor activity in sarcoma therapy.